Modality
Bispecific Ab
MOA
PD-1i
Target
GLP-1R
Pathway
RNA Splicing
IPFCrohn's
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
~Feb 2020
→ ~May 2021
Phase 2
Aug 2021
→ Sep 2031
Phase 2Current
NCT06577185
1,195 pts·IPF
2021-08→2031-09·Recruiting
1,195 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-09-025.4y awayPh2 Data· IPF
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Recruit…
Catalysts
Ph2 Data
2031-09-02 · 5.4y away
IPF
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06577185 | Phase 2 | IPF | Recruiting | 1195 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R |